[{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"1bc7d467-7896-491d-8c0c-8c4bb935a5f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03972657","created_at":"2023-08-08T17:08:39.649Z","updated_at":"2024-07-02T16:35:15.522Z","phase":"Phase 1/2","brief_title":"A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors","source_id_and_acronym":"NCT03972657","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • Kevzara (sarilumab) • nezastomig (REGN5678)"],"overall_status":"Recruiting","enrollment":" Enrollment 345","initiation":"Initiation: 08/12/2019","start_date":" 08/12/2019","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 07/03/2026","study_completion_date":" 07/03/2026","last_update_posted":"2024-03-08"},{"id":"be744523-e7d4-4a11-8136-98abcc13428e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05704634","created_at":"2023-01-30T15:59:29.317Z","updated_at":"2024-07-02T16:35:21.406Z","phase":"Phase 1","brief_title":"A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.","source_id_and_acronym":"NCT05704634","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" STK11","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR exon 18 mutation","tags":["STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • Kevzara (sarilumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 08/18/2023","start_date":" 08/18/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2024-01-31"},{"id":"eeaaa86c-136f-4f91-9901-af1955313aad","acronym":"EMPOWER","url":"https://clinicaltrials.gov/study/NCT04333706","created_at":"2021-01-18T20:59:01.099Z","updated_at":"2024-07-02T16:35:22.962Z","phase":"Phase 1/2","brief_title":"A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)","source_id_and_acronym":"NCT04333706 - EMPOWER","lead_sponsor":"University of Southern California","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • ER positive + PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER positive + PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Kevzara (sarilumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 09/26/2020","start_date":" 09/26/2020","primary_txt":" Primary completion: 11/03/2025","primary_completion_date":" 11/03/2025","study_txt":" Completion: 11/03/2026","study_completion_date":" 11/03/2026","last_update_posted":"2024-01-18"}]